Table 1.
Baseline clinical characteristics and associations with biomarker groups in DF/BWCC
| Patient Cohort | DF/BWCC | |||
|---|---|---|---|---|
| Biomarker Association* | ||||
| Total | 233 | |||
| Age , y | Median (IQR) | 60.1 (53.2–67.7) |
PI3K: (+)64.3 vs (−)59.7; P = .015 | |
| Gender | Male | 126 (54%) | MGMT: Male (M)46% vs (U)65%; P = .02 | |
| Female | 107 (46%) | |||
| KPS | PI3K(+) | PI3K(-); P = .014 | ||
| <60 | 11 (5%) | 2 (3%) | 4 (4%) | |
| 60–80 | 105 (45%) | 46 (65%) | 41 (42%) | |
| 90–100 | 97 (41%) | 23 (32%) | 52 (54%) | |
| Multifocal (%) | No | 199 (85%) | ||
| Yes | 34 (15%) | MGMT: (M)20% vs (U)8%; P = .04 | ||
| Size (cm) | Median (IQR) | 4.2 (3.1–5.3) | p53: (+)3.8 vs (−)4.2; P = .029 | |
| Resection (%) | Biopsy | 17 (7%) | ||
| STR/GTR | 207 (88%) | |||
| Temozolomide (%) | Received | 214 (92%) | ||
| Not received | 12 (5%) | |||
| Alive at 5 y (%) | No | 223 (96%) | ||
| Yes | 10 (4%) | EGFR: (+)0% vs (−)7%; P = .014; p53: (+)10% vs (−)0%; P = .005 | ||
| OS (mo) | Median (IQR) | 20.8 (11.4–50.8) |
MGMT: (M)20.0 vs (U)12.8; P = .036 | |
| PFS (mo) | Median (IQR) | 9.7 (5.7–18.1) |
MGMT: (M)11.6 vs (U)6.9; P = .022; PI3K: (+)9.3 vs (−)10.4; P = .049 |
|
Abbreviations: IQR, interquartile range; STR, subtotal resection; GTR, gross total resection, M, methylated; U, unmethylated.
*
Empty values under biomarker associations indicate no significant clinical associations for any biomarker group.
Note: Table includes only patients with wild-type IDH-1/2 and without 1p/19q codeletion.